The The Drug Cell consortium, led by the French Blood Establishment (EFS), GPI, MGA Technologies, and the AFM-Téléthon Stem Cell Research Center, has secured a record-breaking €152 million funding from the European Union.
The goal: to build a modular and scalable cell therapy manufacturing plant in France by 2031.
Bringing together academic and industrial leaders, including Carroucell and EVerZom, this initiative aims to establish a sovereign European production capability, a field still largely dominated by the U.S. and Asia.
As Hervé de Malliard, CEO of MGA Technologies, states: “Our goal is to democratize access to these costly treatments by automating processes and making production viable in Europe.”
A significant leap forward for innovation and European health independence!
In the Same Category
From Industry to “TechBio”: Our Vision for the Healthcare of Tomorrow
In a recent conversation with Dan Sherrard-Smith for the Founder’s Story podcast, Hervé de Maillard reflected on the core mission of Maison MGA: our obsession with putting complex engineering at the service of life. It all started thirty years ago in China. Between...
Happy Year of the Horse
马年大吉 : Happy Year of the Horse! This Chinese New Year, I think back on my formative years spent in China, from 1994 to 1999. They had a profound impact on my view of the world, industry, and progress. An ancient verse comes to mind: 老骥伏枥，志在千里。 "Even an old horse in...